Nasal irrigation with licorice extract to treat inflammation of the nose and sinuses

Investigating the effect of nasal irrigation with isotonic saline and extract of licorice on treatment of chronic rhinitis and sinusitis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN51425529

Enrollment

300

Registered

2020-04-17

Start date

2018-12-04

Completion date

Unknown

Last updated

2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

allergic rhinitis, non-allergic rhinitis, chronic rhinosinusitis with polyposis, chronic rhinosinusitis without polyposis, nasopharyngeal carcinoma post-radiotherapy complicated with sinusitis Ear, Nose and Throat allergic rhinitis, non-allergic rhinitis, chronic rhinosinusitis with polyposis, chronic rhinosinusitis without polyposis, nasopharyngeal carcinoma post-radiotherapy complicated with sinusitis

Interventions

The study includes five patient groups 1. Allergic rhinitis 2. Non-allergic rhinitis 3. Chronic rhinosinusitis with polyposis 4. Chronic

none=0, mild=1, moderate=2, severe=3, summing scores range from 0 to 12), vi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Diagnosis of allergic or non-allergic rhinitis 2. Diagnosis of chronic rhinosinusitis with or without nasal polyps

Exclusion criteria

Exclusion criteria: 1. Aged <20 years 2. Antihistamine or corticosteroid (oral form or intranasal spray) use within 4 weeks of the intervention 3. Pregnancy 4. Planned sinonasal surgery within 4 weeks of the intervention 5. Allergy to licorice.

Design outcomes

Primary

Measure	Time frame
1. Improvement in nasal obstruction measured by TSS (0-3), VAS (0-100) and SNOT22 at 0, 2 and 4 weeks 2. Improvement in rhinorrhea measured by TSS (0-3), VAS (0-100) and SNOT22 at 0, 2 and 4 weeks 3. Improvement in sneezing measured by TSS (0-3), VAS (0-100) and SNOT22 at 0, 2 and 4 weeks 4. Improvement in itchy nose measured by TSS (0-3), VAS (0-100) and SNOT22 at 0, 2 and 4 weeks 5. Improvement in postnasal drip measured by TSS (0-3), VAS (0-100) and SNOT22 at 0, 2 and 4 weeks 6. Improvement in sleep quality measured by TSS (0-3), VAS (0-100) and SNOT22 at 0, 2 and 4 weeks	—

Measure

Time frame

1. Improvement in nasal obstruction measured by TSS (0-3), VAS (0-100) and SNOT22 at 0, 2 and 4 weeks 2. Improvement in rhinorrhea measured by TSS (0-3), VAS (0-100) and SNOT22 at 0, 2 and 4 weeks 3. Improvement in sneezing measured by TSS (0-3), VAS (0-100) and SNOT22 at 0, 2 and 4 weeks 4. Improvement in itchy nose measured by TSS (0-3), VAS (0-100) and SNOT22 at 0, 2 and 4 weeks 5. Improvement in postnasal drip measured by TSS (0-3), VAS (0-100) and SNOT22 at 0, 2 and 4 weeks 6. Improvement in sleep quality measured by TSS (0-3), VAS (0-100) and SNOT22 at 0, 2 and 4 weeks

—

Secondary

Measure	Time frame
1. Nasal condition measured by nasal endoscopic examination, which is scored by using Lund Kennedy endoscopic scoring system, at 0, 2 and 4 weeks 2. Nasal resistance measured using acoustic rhinometry at 0, 2 and 4 weeks 3. Analysis of cytokines in the nasal discharge at 0, 2 and 4 weeks	—

Countries

Taiwan

Contacts

Public ContactGeng-He Chang

genghechang@gmail.com+886 5 362 1000 ext. 2076

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 12, 2026